We additionally found that activation of CD4 + T cells and M1 macrophages can promote anti-tumor immunity and have low infiltration in EGFR mutated NSCLC, which could limit the killing efficiency of CD8 + T cells. The gene discussed is CD4; the disease is non-small cell lung carcinoma.